A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Overview
- Phase
- Phase 1
- Intervention
- chemotherapy
- Conditions
- Malignancies
- Sponsor
- AbbVie
- Enrollment
- 143
- Locations
- 31
- Primary Endpoint
- Number of Participants Experiencing Adverse Events
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants must have relapsed or refractory cancer.
- •Participants must have adequate hepatic and kidney function.
- •Participants less than or equal to 16 years of age must have performance status of Lansky greater than or equal to 50% and participants greater than 16 years of age must have performance status of Karnofsky greater than or equal to 50%.
- •Participants with solid tumors (with the exception of neuroblastoma) must have adequate bone marrow function in Part
- •For the fifth cohort during Part 2 Cohort Expansion, participants with solid tumors must have evidence of BCL-2 expression (except participants with TCF3-HLF ALL).
Exclusion Criteria
- •Participants with primary brain tumors or disease metastatic to the brain.
- •Participants who have central nervous system (CNS) disease with cranial involvement that requires radiation.
- •Participants who have received any of the following within the listed time frame, prior to the first dose of study drug
- •Inotuzumab ozogamicin or gemtuzumab ozogamicin within 30 days
- •Biologic agent (i.e., antibodies) for anti-neoplastic intent within 30 days or 5 half-lives whichever is shorter.
- •CAR-T infusion or other cellular therapy within 30 days
- •Anticancer therapy including chemotherapy, radiation therapy, targeted small molecule agents, investigational agents within 14 days or 5 half-lives, whichever is shorter (Exceptions: Ph+ALL participants on Tyrosine Kinase Inhibitor (TKI) at Screening may enroll and remain on TKI therapy to control disease and TCF3-HLF ALL participants are allowed to have received chemotherapy within 14 days or 5 half-lives, whichever is shorter).
- •Steroid therapy for anti-neoplastic intent within 5 days (with the exception of TCF3-HLF ALL participants).
- •Requires ongoing hydroxyurea (hydroxyurea permitted up to first dose)
- •Participants who are less than 100 days post-transplant, or greater than or equal to 100 days post-transplant with active graft versus host disease (GVHD), or are receiving immunosuppressant therapy within 7 days prior to first dose of study drug.
Arms & Interventions
Venetoclax with or without chemotherapy
Venetoclax administered orally once daily (QD) with various doses and dosing regimens with or without chemotherapy at the discretion of the investigator. Allowed chemotherapy regimens as outlined in the study protocol.
Intervention: chemotherapy
Venetoclax with or without chemotherapy
Venetoclax administered orally once daily (QD) with various doses and dosing regimens with or without chemotherapy at the discretion of the investigator. Allowed chemotherapy regimens as outlined in the study protocol.
Intervention: venetoclax
Outcomes
Primary Outcomes
Number of Participants Experiencing Adverse Events
Time Frame: Up to 9 months
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Number of Participants With Dose Limiting Toxicities (DLT) of Venetoclax Monotherapy
Time Frame: First 21 days venetoclax monotherapy
A DLT is any Grade 3 or higher non-hematologic adverse event (AE) with exceptions outlined in the protocol.
Recommended Phase 2 dose (RPTD) of Venetoclax
Time Frame: First 21 days venetoclax monotherapy
Venetoclax RPTD is the dose determined based on adverse event reporting and dose-limiting toxicity information from all participants.
Cmax of Venetoclax
Time Frame: Up to approximately 2 weeks
Maximum plasma concentration (Cmax) of venetoclax.
Tmax of venetoclax
Time Frame: Up to approximately 2 weeks
Time to maximum plasma concentration (Tmax) of venetoclax.
AUC0-24 Post-Dose of Venetoclax
Time Frame: Up to approximately 2 weeks
Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax.
Secondary Outcomes
- Partial Response (PR) Rate(Up to 9 months)
- Objective Response Rate (ORR)(Up to 9 months)
- Complete Response (CR) Rate(Up to 9 months)